Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.940
-0.120 (-3.92%)
Jul 11, 2025, 1:34 PM - Market open

Editas Medicine Statistics

Total Valuation

Editas Medicine has a market cap or net worth of $246.12 million. The enterprise value is $46.24 million.

Market Cap 246.12M
Enterprise Value 46.24M

Important Dates

The next estimated earnings date is Wednesday, August 6, 2025, before market open.

Earnings Date Aug 6, 2025
Ex-Dividend Date n/a

Share Statistics

Editas Medicine has 83.71 million shares outstanding. The number of shares has increased by 4.29% in one year.

Current Share Class 83.71M
Shares Outstanding 83.71M
Shares Change (YoY) +4.29%
Shares Change (QoQ) +0.53%
Owned by Insiders (%) 0.40%
Owned by Institutions (%) 53.50%
Float 83.38M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 7.05
Forward PS 17.49
PB Ratio 4.10
P/TBV Ratio 3.78
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 1.29
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.08, with a Debt / Equity ratio of 0.50.

Current Ratio 3.08
Quick Ratio 3.03
Debt / Equity 0.50
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -93.52

Financial Efficiency

Return on equity (ROE) is -140.82% and return on invested capital (ROIC) is -61.37%.

Return on Equity (ROE) -140.82%
Return on Assets (ROA) -36.80%
Return on Invested Capital (ROIC) -61.37%
Return on Capital Employed (ROCE) -108.77%
Revenue Per Employee $145,679
Profits Per Employee -$1.02M
Employee Count 246
Asset Turnover 0.10
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -42.32% in the last 52 weeks. The beta is 2.16, so Editas Medicine's price volatility has been higher than the market average.

Beta (5Y) 2.16
52-Week Price Change -42.32%
50-Day Moving Average 1.95
200-Day Moving Average 1.98
Relative Strength Index (RSI) 69.02
Average Volume (20 Days) 3,451,083

Short Selling Information

The latest short interest is 8.43 million, so 10.07% of the outstanding shares have been sold short.

Short Interest 8.43M
Short Previous Month 9.00M
Short % of Shares Out 10.07%
Short % of Float 10.11%
Short Ratio (days to cover) 4.26

Income Statement

In the last 12 months, Editas Medicine had revenue of $35.84 million and -$251.23 million in losses. Loss per share was -$3.04.

Revenue 35.84M
Gross Profit -161.41M
Operating Income -207.24M
Pretax Income -193.45M
Net Income -251.23M
EBITDA -200.92M
EBIT -207.24M
Loss Per Share -$3.04
Full Income Statement

Balance Sheet

The company has $220.96 million in cash and $31.13 million in debt, giving a net cash position of $189.83 million or $2.27 per share.

Cash & Cash Equivalents 220.96M
Total Debt 31.13M
Net Cash 189.83M
Net Cash Per Share $2.27
Equity (Book Value) 62.42M
Book Value Per Share 0.75
Working Capital 151.73M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$208.21 million and capital expenditures -$7.07 million, giving a free cash flow of -$215.28 million.

Operating Cash Flow -208.21M
Capital Expenditures -7.07M
Free Cash Flow -215.28M
FCF Per Share -$2.57
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -578.28%
Pretax Margin -701.04%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Editas Medicine does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -4.29%
Shareholder Yield -4.29%
Earnings Yield -106.42%
FCF Yield -91.19%

Analyst Forecast

The average price target for Editas Medicine is $6.20, which is 110.88% higher than the current price. The consensus rating is "Buy".

Price Target $6.20
Price Target Difference 110.88%
Analyst Consensus Buy
Analyst Count 12
Revenue Growth Forecast (5Y) -12.72%
EPS Growth Forecast (5Y) -17.95%
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Editas Medicine has an Altman Z-Score of -9.1 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -9.1
Piotroski F-Score 1